iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE – Get Free Report) shares hit a new 52-week high during mid-day trading on Thursday. The stock traded as high as $109.84 and last traded at $110.3080, with a volume of 14,879 shares. The stock had previously closed at $109.09.
iShares U.S. Pharmaceuticals ETF Price Performance
The firm has a market cap of $1.62 billion, a PE ratio of 17.75 and a beta of 0.47. The stock’s fifty day moving average price is $102.45 and its 200-day moving average price is $95.06.
Institutional Trading of iShares U.S. Pharmaceuticals ETF
Several large investors have recently bought and sold shares of the business. MinichMacGregor Wealth Management LLC acquired a new stake in iShares U.S. Pharmaceuticals ETF in the 3rd quarter valued at about $32,098,000. Cetera Investment Advisers lifted its stake in iShares U.S. Pharmaceuticals ETF by 675.4% in the 1st quarter. Cetera Investment Advisers now owns 109,471 shares of the company’s stock worth $9,489,000 after purchasing an additional 95,353 shares in the last quarter. Virtue Capital Management LLC acquired a new position in shares of iShares U.S. Pharmaceuticals ETF during the 3rd quarter worth approximately $6,239,000. Congress Asset Management Co. acquired a new position in shares of iShares U.S. Pharmaceuticals ETF during the 3rd quarter worth approximately $56,000. Finally, AdvisorNet Financial Inc acquired a new position in shares of iShares U.S. Pharmaceuticals ETF during the 3rd quarter worth approximately $5,224,000.
iShares U.S. Pharmaceuticals ETF Company Profile
iShares U.S. Pharmaceuticals ETF, formerly iShares Dow Jones U.S. Pharmaceuticals Index Fund (the Fund), is an exchange traded fund. The Fund seeks investment results that correspond generally to the price and yield performance of the Dow Jones U.S. Select Pharmaceuticals Index (the Index). The Index measures the performance of the pharmaceuticals sector of the United States equity market, and includes pharmaceutical companies such as manufacturers of prescription or over-the-counter drugs or vaccines, but excludes producers of vitamins.
Further Reading
- Five stocks we like better than iShares U.S. Pharmaceuticals ETF
- Uber’s Profit Drop: A Speed Bump or Structural Shift?
- Boeing Has the Orders, the Cash Flow, and Insider Buyers, But What’s Still Missing?
- The Fed Is Split on Rates—Why These 2 Treasury ETFs Could Have an Edge
- Gold’s 2026 Pullback Raises a Bigger Question: Buy the Metal or the Miners?
Receive News & Ratings for iShares U.S. Pharmaceuticals ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares U.S. Pharmaceuticals ETF and related companies with MarketBeat.com's FREE daily email newsletter.
